{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:50:53Z","timestamp":1794293453519,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","award":["RN2239"],"award-info":[{"award-number":["RN2239"]}],"id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02019-7","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T13:17:51Z","timestamp":1749734271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica"],"prefix":"10.1186","volume":"13","author":[{"given":"Katherine S","family":"Given","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"publisher","unstructured":"Almeida RG, Pan S, Cole KLH, Williamson JM, Early JJ, Czopka T, Klingseisen A, Chan JR, Lyons DA (2018) Myelination of Neuronal Cell Bodies when Myelin Supply Exceeds Axonal Demand. Curr Biol 28: 1296\u20131305 e1295 https:\/\/doi.org\/10.1016\/j.cub.2018.02.068","DOI":"10.1016\/j.cub.2018.02.068"},{"key":"2019_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"J Bennett","year":"2009","unstructured":"Bennett J, Lam C, Kalluri S, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel J, Owens Get al et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629. https:\/\/doi.org\/10.1002\/ana.21802","journal-title":"Ann Neurol"},{"key":"2019_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, Merle H, Ferge JL, Mehdaoui H, Cabre P (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346\u2013351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1523\/JNEUROSCI.5218-14.2015","volume":"35","author":"FH Brennan","year":"2015","unstructured":"Brennan FH, Gordon R, Lao HW, Biggins PJ, Taylor SM, Franklin RJ, Woodruff TM, Ruitenberg MJ (2015) The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J Neurosci 35:6517\u20136531. https:\/\/doi.org\/10.1523\/JNEUROSCI.5218-14.2015","journal-title":"J Neurosci"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","volume":"13","author":"S Chatterton","year":"2022","unstructured":"Chatterton S, Parratt JDE, Ng K (2022) Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol 13:951423. https:\/\/doi.org\/10.3389\/fneur.2022.951423","journal-title":"Front Neurol"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1172\/JCI134816","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen T, Lennon VA, Liu YU, Bosco DB, Li Y, Yi MH, Zhu J, Wei S, Wu LJ (2020) Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest 130:4025\u20134038. https:\/\/doi.org\/10.1172\/JCI134816","journal-title":"J Clin Invest"},{"key":"2019_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","volume":"15","author":"T Duan","year":"2018","unstructured":"Duan T, Smith AJ, Verkman AS (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294. https:\/\/doi.org\/10.1186\/s12974-018-1333-z","journal-title":"J Neuroinflammation"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40478-019-0766-7","volume":"7","author":"T Duan","year":"2019","unstructured":"Duan T, Smith AJ, Verkman AS (2019) Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun 7:112. https:\/\/doi.org\/10.1186\/s40478-019-0766-7","journal-title":"Acta Neuropathol Commun"},{"key":"2019_CR9","doi-asserted-by":"publisher","unstructured":"Enriquez M, Rosenthal S, McLendon L, Bennett J, Piquet A, Kammeyer R (2024) Efficacy of Eculizumab in acute refractory pediatric neuromyelitis optica: A case report. Neuroimmunol Rep 5. https:\/\/doi.org\/10.1016\/j.nerep.2024.100213","DOI":"10.1016\/j.nerep.2024.100213"},{"key":"2019_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.18.594292","author":"M Herwerth","year":"2024","unstructured":"Herwerth M, Wyss MT, Schmid NB, Condrau J, Ravotto L, Mateos Melero JM, Kaech A, Bredell G, Thomas C, Stadelmann Cet al et al (2024) Astrocytes adopt a progenitor-like migratory strategy for regeneration in adult brain. BioRxiv: Doi. https:\/\/doi.org\/10.1101\/2024.05.18.594292","journal-title":"BioRxiv: Doi"},{"key":"2019_CR11","first-page":"535","volume":"84","author":"G Hetland","year":"1991","unstructured":"Hetland G, Mollnes TE, Garred P (1991) Activation of complement during apheresis. Clin Exp Immunol 84:535\u2013538","journal-title":"Clin Exp Immunol"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1073\/pnas.1701960114","volume":"114","author":"SR Hinson","year":"2017","unstructured":"Hinson SR, Clift IC, Luo N, Kryzer TJ, Lennon VA (2017) Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor. Proc Natl Acad Sci U S A 114:5491\u20135496. https:\/\/doi.org\/10.1073\/pnas.1701960114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41593-020-0654-2","volume":"23","author":"AN 13 Hughes","year":"2020","unstructured":"13 Hughes AN, Appel B (2020) Microglia phagocytose myelin sheaths to modify developmental myelination. Nat Neurosci 23:1055\u20131066. https:\/\/doi.org\/10.1038\/s41593-020-0654-2","journal-title":"Nat Neurosci"},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molimm.2010.08.007","volume":"48","author":"SA Ingersoll","year":"2010","unstructured":"Ingersoll SA, Martin CB, Barnum SR, Martin BK (2010) CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model. Mol Immunol 48:219\u2013230. https:\/\/doi.org\/10.1016\/j.molimm.2010.08.007","journal-title":"Mol Immunol"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6:85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9","journal-title":"Nat Rev Dis Primers"},{"key":"2019_CR16","doi-asserted-by":"publisher","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kumpfel T et al (2018) Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5: e504 https:\/\/doi.org\/10.1212\/NXI.0000000000000504","DOI":"10.1212\/NXI.0000000000000504"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1084\/jem.20141656","volume":"212","author":"A Lampron","year":"2015","unstructured":"Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG, Yong VW, Stys PK, Tremblay ME, Rivest S (2015) Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212:481\u2013495. https:\/\/doi.org\/10.1084\/jem.20141656","journal-title":"J Exp Med"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","volume":"1","author":"M Levy","year":"2014","unstructured":"Levy M, Mealy MA (2014) Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 1:e5. https:\/\/doi.org\/10.1212\/NXI.0000000000000005","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/glia.23512","volume":"66","author":"Y Liu","year":"2018","unstructured":"Liu Y, Given KS, Owens GP, Macklin WB, Bennett JL (2018) Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. Glia 66:2575\u20132588. https:\/\/doi.org\/10.1002\/glia.23512","journal-title":"Glia"},{"key":"2019_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12974-016-0767-4","volume":"13","author":"Y Liu","year":"2016","unstructured":"Liu Y, Harlow DE, Given KS, Owens GP, Macklin WB, Bennett JL (2016) Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. J Neuroinflammation 13:301. https:\/\/doi.org\/10.1186\/s12974-016-0767-4","journal-title":"J Neuroinflammation"},{"key":"2019_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1523\/JNEUROSCI.22-03-00876.2002","volume":"22","author":"BS Mallon","year":"2002","unstructured":"Mallon BS, Shick HE, Kidd GJ, Macklin WB (2002) Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J Neurosci 22:876\u2013885","journal-title":"J Neurosci"},{"key":"2019_CR22","doi-asserted-by":"publisher","unstructured":"Molina-Gonzalez I, Holloway RK, Jiwaji Z, Dando O, Kent SA, Emelianova K, Lloyd AF, Forbes LH, Mahmood A, Skripuletz T et al (2023) Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration. Nat Commun 14: 3372 https:\/\/doi.org\/10.1038\/s41467-023-39046-8","DOI":"10.1038\/s41467-023-39046-8"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3389\/fimmu.2018.01694","volume":"9","author":"P Piatek","year":"2018","unstructured":"Piatek P, Domowicz M, Lewkowicz N, Przygodzka P, Matysiak M, Dzitko K, Lewkowicz P (2018) C5a-Preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder. Front Immunol 9:1694. https:\/\/doi.org\/10.3389\/fimmu.2018.01694","journal-title":"Front Immunol"},{"key":"2019_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de Seze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul Fet al et al (2023) Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol 93:1053\u20131068. https:\/\/doi.org\/10.1002\/ana.26626","journal-title":"Ann Neurol"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan Set al et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","volume":"10","author":"K Prain","year":"2019","unstructured":"Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett MH, Bundell CS, Parratt JDE, Silvestrini RA, Bukhari W, Australianet al (2019) AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol 10:1028. https:\/\/doi.org\/10.3389\/fneur.2019.01028","journal-title":"Front Neurol"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","volume":"126","author":"J Ratelade","year":"2013","unstructured":"Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS (2013) Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol 126:699\u2013709. https:\/\/doi.org\/10.1007\/s00401-013-1172-z","journal-title":"Acta Neuropathol"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123:861\u2013872. https:\/\/doi.org\/10.1007\/s00401-012-0986-4","journal-title":"Acta Neuropathol"},{"key":"2019_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.07.009","volume":"180","author":"H Rus","year":"2006","unstructured":"Rus H, Cudrici C, Niculescu F, Shin ML (2006) Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 180:9\u201316","journal-title":"J Neuroimmunol"},{"key":"2019_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41577-021-00621-z","volume":"21","author":"B Stevens","year":"2021","unstructured":"Stevens B, Johnson MB (2021) The complement cascade repurposed in the brain. Nat Rev Immunol 21:624\u2013625. https:\/\/doi.org\/10.1038\/s41577-021-00621-z","journal-title":"Nat Rev Immunol"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, Bennett JL, Verkman AS (2012) Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314\u2013322. https:\/\/doi.org\/10.1002\/ana.22657","journal-title":"Ann Neurol"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0165-5728(96)00110-5","volume":"70","author":"LJ van der Laan","year":"1996","unstructured":"van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD (1996) Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J Neuroimmunol 70:145\u2013152.","journal-title":"J Neuroimmunol"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1537-2995.1982.22182154218.x","volume":"22","author":"RL Volkin","year":"1982","unstructured":"Volkin RL, Starz TW, Winkelstein A, Shadduck RK, Lewis JH, Hasiba U, Spero JA (1982) Changes in coagulation factors, complement, Iimmunoglobulins, and immune complex concentrations with plasma exchange. Transfusion 22:54\u201358. https:\/\/doi.org\/10.1046\/j.1537-2995.1982.22182154218.x","journal-title":"Transfusion"},{"key":"2019_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/jca.2920030209","volume":"3","author":"L Wood","year":"1986","unstructured":"Wood L, Jacobs P (1986) The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. J Clin Apheresis 3:124\u2013128. https:\/\/doi.org\/10.1002\/jca.2920030209","journal-title":"J Clin Apheresis"},{"key":"2019_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00401-013-1220-8","volume":"127","author":"C Wrzos","year":"2014","unstructured":"Wrzos C, Winkler A, Metz I, Kayser DM, Thal DR, Wegner C, Bruck W, Nessler S, Bennett JL, Stadelmann C (2014) Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol 127:523\u2013538. https:\/\/doi.org\/10.1007\/s00401-013-1220-8","journal-title":"Acta Neuropathol"},{"key":"2019_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-016-0309-4","volume":"4","author":"X Yao","year":"2016","unstructured":"Yao X, Su T, Verkman AS (2016) Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta Neuropathol Commun 4:42. https:\/\/doi.org\/10.1186\/s40478-016-0309-4","journal-title":"Acta Neuropathol Commun"},{"key":"2019_CR37","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang H, Verkman AS (2013) Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123:2306\u20132316. https:\/\/doi.org\/10.1172\/JCI67554","journal-title":"J Clin Invest"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02019-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T13:17:52Z","timestamp":1749734272000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02019-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02019-7","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animals were performed in accordance with University of Colorado Institutional Animal Care and Use Committee policy for animal use in agreement with the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KSG- None EA- None WBM- None DC - is an employee and shareholder of Alexion, AstraZeneca Rare Disease GPO- None JLB \u2013 reports personal fees from Alexion AstraZeneca Rare Disease, Antigenomycs, BeiGene, Chugai, Clene Nanomedicine, Genentech, Genzyme, Reistone Bio, Roche, Imcyse, Mitsubishi-Tanabe, and TG; speaker fees from Alexion; grants from Alexion and the National Institutes of Health. In addition, Dr Bennett has a patent \u2018Compositions and methods for the treatment of neuromyelitis optica\u2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}